BioWorld MedTech

Aug. 6, 2014

NewCo on the Go: A nosy new technology may offer solution for Alzheimer's disease

A nose device designed to target nerve trunks and stimulate the brain structures that control memory and cognition is catching attention as a potential new therapy for central nervous system diseases, including Alzheimer's. Read More

Philips, Accenture partnership could give ALS patients more independence

Inside the Beltway: CMS says no to new DRG for MitraClip, Abbott unenthused

World in Brief: Lombard's Aorfix will begin sales of AAA grafts in Japan

Agreements/contracts: CareView in pilot patient monitoring agreement with Shea Medical Center

Daily M&A: Varian acquires assets of Transpire, including Acuros

Grants: Oraya receives $215K small business grant from NIH for Oraya Therapy

People in Places

Hit Bits: Healthways and Gallup reach new milestone in joint venture

Product briefs

MDD's Oncology Extra

Today's news in brief

BioWorld

BioWorld briefs for April 4, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 4, 2025.

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

3D rendering of glucagon-like peptide 1 (GLP-1)

ADPD 2025: Unlocking GLP-1's potential in neurodegeneration

BioWorld

At the recently launched Alzheimer’s & Parkinson’s Diseases Conference held in Vienna, Lotte Bjerre Knudsen from Novo Nordisk A/S, who has extensive experience in...

Immune checkpoint inhibitors illustration of PD-1, CTLA-4 and PD-L1.

Checkpoint inhibitor journey traces Chinese firms’ path to global revenue

BioWorld

Chinese pharmaceutical companies are making significant inroads into the global oncology market, particularly with the development and approval of immune...